CytoSorb® / CytoSorb 300®
Reduction of elevated cytokines, bilirubin, myoglobin; Removal of Ticagrelor/Rivaroxaban during cardio-pulmonary bypass surgery
Approved (CE Mark)Commercial in EU/International; Investigational in U.S.
Key Facts
Indication
Reduction of elevated cytokines, bilirubin, myoglobin; Removal of Ticagrelor/Rivaroxaban during cardio-pulmonary bypass surgery
Phase
Approved (CE Mark)
Status
Commercial in EU/International; Investigational in U.S.
Company
About CytoSorbents
CytoSorbents is a public company (NASDAQ: CTSO) pioneering blood purification to treat life-threatening conditions in intensive care and cardiac surgery. Its core technology uses highly porous polymer beads to adsorb harmful substances from blood, complementing conventional dialysis. While CytoSorb® is commercially available in over 75 countries with a CE mark, the company is actively pursuing FDA approval for its devices in the United States, representing a significant future growth opportunity.
View full company profile